Novartis Breakfast Symposium: Beyond targets: The Real-World Impact of ASCVD in New Zealand
Tracks
Matiu Meeting Room
| Friday, June 12, 2026 |
| 7:15 AM - 8:15 AM |
| Matiu Meeting Room |
Details
Despite clear guidelines, many ASCVD patients in New Zealand remain sub optimally treated, with significant consequences for long-term outcomes. This session will explore the real-world impact of not achieving LDL-C targets, alongside emerging data and local insights that challenge current approaches to secondary prevention.
Through expert perspectives and discussion, we will examine how clinicians can move beyond targets to deliver more meaningful reductions in LDL-C and what needs to change in New Zealand to make this a reality.
Speaker
Prof Ralph Stewart
Cardiologist
Auckland City Hospital
Welcome and Overview
7:15 AM - 8:15 AMBiography
Prof Ralph Stewart is a Cardiologist at The Heart Group and Auckland City Hospital, and an Honorary Professor of Medicine, University of Auckland. He has interests across cardiology including coronary artery disease, risk assessment and management, heart valve disease, heart failure, and atrial fibrillation. He is a past Chairman of both the NZ Cardiac Society and the National Cardiac Clinical Network and continues to lead and contribute to national and international clinical research to improve outcomes for people with heart disease
Prof Scott Harding
Cardiologist
Wellington Hospital
New Zealand new data on the significant impact of subsequent ASCVD events to the NZ health system
7:15 AM - 8:15 AMBiography
Professor Harding is the Director of Cardiology Research, and an Interventional Cardiologist at Wellington Hospital , Wellington, New Zealand. He is an Adjunct Professor at the School of Biological Sciences, Victoria University, Wellington. Professor Harding undertook cardiology an interventional training in Wellington Hospital, the Royal Infirmary of Edinburgh, and at the Massachusetts General Hospital. Professor Harding has lectured on and proctored complex PCI, CTO and intravascular imaging internationally. Current research interests include, intravascular imaging, optimising PCI and platelet biology. He is an active researcher having published more than 140 papers.
A/Prof. Adam Nelson
The Royal Adelaide Hospital
Bridging the Treatment Gap in ASCVD: The Role of Advanced Lipid-Lowering
7:15 AM - 8:15 AMBiography
Adam Nelson MBBS MBA MPH PhD is an interventional and preventative cardiologist appointed to the Royal Adelaide and Queen Elizabeth Hospitals and the University of Adelaide where he is the head of the Cardiometabolic Clinical Trial Unit. Adam is the chair of the CSANZ Prevention Council and Academic Lead of the Asia Pacific Cardiometabolic Consortium. Adam is on the national or global leadership of multiple trials evaluating emerging therapies for dyslipidaemia, obesity and diabetes. He is the recipient of >$10millon of peer-reviewed grant funding and received the Shirley Hamilton Award for the National Heart Foundation top ranked post-doctoral fellowship candidate. He has over 200 publications and book chapters but is most proud of his two boys, Archer and Max.